CXCR4 and neuropathy: In the same way, Deng et al., 2012 [64], in a chemotherapy-induced neuropathy model with cisplatin and paclitaxel, concluded that CXCR4 signaling did not contribute to the maintenance of chemotherapy-induced neuropathy, and that blocking CXCR4 signaling with AMD3100 failed to reverse the established chemotherapy-induced neuropathy [65].